Recce Pharmaceuticals Completes Capital Raising of $27.95 Million
Highlights:
See more here:
Recce Pharmaceuticals Completes Capital Raising of $27.95 Million
Category Archives: Global News Feed
Simplify Medical Receives FDA Approval for 1-Level Simplify Disc PMA
Simplify Disc overall success rate of 93.0% was superior to the ACDF control Simplify Disc overall success rate of 93.0% was superior to the ACDF control
View original post here:
Simplify Medical Receives FDA Approval for 1-Level Simplify Disc PMA
Kiadis announces results for the six months ended June 30, 2020 and significant progress made to date in 2020 in all development programs
Amsterdam, The Netherlands, September 30, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company focused on the development of innovative natural killer (NK) cell-based medicines for the treatment of life-threatening diseases, today announces its unaudited interim results for the six months ended June 30, 2020, which have been prepared in accordance with International Financial Reporting Standards (IFRS) as adopted by the European Union.
Go here to read the rest:
Kiadis announces results for the six months ended June 30, 2020 and significant progress made to date in 2020 in all development programs
Strong operating performance continues as Golden Leaf Holdings expects to report a successive record revenue quarter and positive cash flow from…
Q3 2020 Selected Year-to-date results Q3 2020 Selected Year-to-date results
View original post here:
Strong operating performance continues as Golden Leaf Holdings expects to report a successive record revenue quarter and positive cash flow from...
Freeline to participate in Chardan’s 4th Annual Genetic Medicines Conference
LONDON, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, today announced that Theresa Heggie, Chief Executive Officer, will present at the Chardan Virtual 4th Annual Global Healthcare Conference on October 6 at 4:45pm EDT.
Link:
Freeline to participate in Chardan’s 4th Annual Genetic Medicines Conference
OKYO Pharma Limited ("OKYO" or the "Company") – Result of the Annual General Meeting
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014
Follow this link:
OKYO Pharma Limited ("OKYO" or the "Company") - Result of the Annual General Meeting
Surrozen Expands Board of Directors with Appointment of David J. Woodhouse, Ph.D.
SOUTH SAN FRANCISCO, Calif., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced the addition of David J. Woodhouse, Ph.D., to the Board of Directors. Dr. Woodhouse currently serves as the chief executive officer and a director of NGM Biopharmaceuticals.
Read the original post:
Surrozen Expands Board of Directors with Appointment of David J. Woodhouse, Ph.D.
Capricor Therapeutics to Present Results from the HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at the International World Muscle Society…
--Final 12-Month Results from Phase II Trial to be Presented on October 1--LOS ANGELES, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases, announced today that the Company will present novel data from its randomized, double-blind, Phase II HOPE-2 clinical trial with its lead investigational product, CAP-1002, in boys and young men with Duchenne muscular dystrophy (DMD).
Here is the original post:
Capricor Therapeutics to Present Results from the HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at the International World Muscle Society...
Galecto Raises $64 Million to Accelerate Development of Clinical Pipeline
Funds will support preparations for potential EU conditional approval of GB0139 in IPF and multiple new Phase 2 clinical trials Funds will support preparations for potential EU conditional approval of GB0139 in IPF and multiple new Phase 2 clinical trials
Read more:
Galecto Raises $64 Million to Accelerate Development of Clinical Pipeline